Key Takeaways
- Rejuran (PN): repair and skin quality. Juvelook (PDLLA): collagen and firmness
- Downtime differs in kind — Rejuran: 1–3 days embossing; Juvelook: a few days of swelling
- Rejuran is a shorter, more frequent course; Juvelook is fewer sessions that last longer
- Head-to-head evidence is limited — figures are best treated as ranges
Walk into a Seoul clinic asking for "a skin booster" and you will quickly meet two names: Rejuran and Juvelook. They sit side by side on the same menu, they are both injected, and they are both discussed as ways to improve skin quality rather than reshape the face. That is roughly where the similarity ends.
The useful question is not which one is better. It is which one fits what you actually want to change — and how much downtime, and how many visits, you are willing to budget for.
Two boosters, two different molecules
Rejuran is a polynucleotide (PN) product — long fragments of DNA purified from salmon or trout. Juvelook is a poly-D,L-lactic acid (PDLLA) product: microparticles of a synthetic, biodegradable polymer suspended in a carrier of non-cross-linked hyaluronic acid. Same shelf, completely different raw material — one biological, one synthetic.
How do they actually work?
Rejuran — a repair signal
Rejuran is described in clinical sources as behaving like a repair signal. As the polynucleotides break down, they are described as releasing nucleotides that act on the skin's own machinery — calming inflammation and supporting the cells that maintain skin quality. The stated aim is texture, hydration, and resilience, rather than added volume.
Juvelook — a collagen prompt
Juvelook is described as working by prompting collagen. The PDLLA microparticles are characterised as creating a controlled, temporary presence that the body responds to by laying down new collagen around them, with the particles themselves described as dissolving over months. The hyaluronic acid carrier adds a little hydration early on — easy to mistake for the PDLLA working immediately.
Side-by-side comparison
| Rejuran (PN) | Juvelook (PDLLA) | |
|---|---|---|
| Raw material | Salmon DNA fragments | PDLLA microparticles + HA carrier |
| Mechanism | Repair signalling | Collagen stimulation |
| Best for | Dry, dull, reactive; post-laser | Early laxity, firmness, enlarged pores |
| Downtime | 1–3 days embossing | Few days swelling; occasional nodules |
| Course | 3–4 sessions, 2–4 wks apart | 2–3 sessions, 4–6 wks apart |
| Reported duration | 3–6 months | ~12–18 months |
| Fish allergy | Relevant — raise with provider | Not salmon-derived |
| HA present | No | Yes (carrier, early effect) |
What is the downtime for each?
Rejuran's most commonly reported downtime is embossing — small raised bumps where the product was placed, which are generally described as settling within about one to three days. Because Rejuran is placed in the upper layers of the skin, it is commonly described as stinging even with numbing cream.
Juvelook is commonly described with more ordinary injection downtime — some swelling or bruising for a few days — and, less commonly, small firm lumps (nodules) whose likelihood is discussed as influenced by injection technique. Placed with a fine cannula, it is often described as more comfortable in the moment than Rejuran.
If your downtime budget is "I have dinner tomorrow night," Rejuran's bumps are the thing to plan around. If it is "I can lie low for a long weekend," Juvelook's swelling is easy to absorb.
So which one fits you?
If the concern is dry, sensitive, dull skin — or skin recovering from lasers or acne scars — and the goal is improving quality without changing shape, Rejuran is commonly described as the more natural fit. If the concern is early laxity, enlarged pores, or a loss of firmness, and there is patience for a slow build, Juvelook is commonly discussed as aimed at that.
Ask about your skin, not just the brand
Bring the concern to the consultation instead of the brand name, and the choice tends to make itself. And if the answer turns out to be a bit of both, in the right order, that is a common place to land.
Sources ▶ 1) Park et al. — "Polydeoxyribonucleotides as Emerging Therapeutics," Applied Sciences (2025); 2) Nguyen Ngan Giang et al. — Polynucleotide and microparticle biostimulators mouse model study, Aesthetic Plastic Surgery 49:5611–5622 (2025); 3) Journal of Cutaneous and Aesthetic Surgery — PDRN narrative review.
